211 related articles for article (PubMed ID: 38108945)
1. Use of the National Cancer Institute Patient-Reported Outcomes version of the Common Terminology Criteria for Adverse Events to assess treatment tolerability in pulmonary arterial hypertension: qualitative patient research findings in current and former users of oral selexipag.
Davis S; Edwards T; Norcross L; Fehnel S; Beaudet A; Eckart M; Fastenau J
J Patient Rep Outcomes; 2023 Dec; 7(1):134. PubMed ID: 38108945
[TBL] [Abstract][Full Text] [Related]
2. Cognitive interviewing of the US National Cancer Institute's Patient-Reported Outcomes version of the Common Terminology Criteria for Adverse Events (PRO-CTCAE).
Hay JL; Atkinson TM; Reeve BB; Mitchell SA; Mendoza TR; Willis G; Minasian LM; Clauser SB; Denicoff A; O'Mara A; Chen A; Bennett AV; Paul DB; Gagne J; Rogak L; Sit L; Viswanath V; Schrag D; Basch E;
Qual Life Res; 2014 Feb; 23(1):257-69. PubMed ID: 23868457
[TBL] [Abstract][Full Text] [Related]
3. Integrating the patient voice with clinician reports to identify a hepatocellular carcinoma-specific subset of treatment-related symptomatic adverse events.
Speck RM; Lenderking WR; Shaw JW
J Patient Rep Outcomes; 2017; 2():35. PubMed ID: 30175317
[TBL] [Abstract][Full Text] [Related]
4. Reliability and Validity of the Korean Language Version of the U.S. National Cancer Institute's Patient-Reported Outcomes Common Terminology Criteria for Adverse Events.
Yoon J; Sim SH; Kang D; Han G; Kim Y; Ahn J; Oh D; Lee ES; Kong SY; Cho J; Mitchell SA
J Pain Symptom Manage; 2020 May; 59(5):1082-1088.e6. PubMed ID: 32044423
[TBL] [Abstract][Full Text] [Related]
5. Identifying symptomatic adverse events using the patient-reported outcomes version of the common terminology criteria for adverse events in patients with non-small cell lung cancer with epidermal growth factor receptor exon 20 insertion mutations.
Zhu Y; Jean-Baptiste M; Lenderking WR; Bell JA; Revicki DA; Lin HM; Brake R; Reeve BB
Cancer Med; 2023 Mar; 12(5):5494-5505. PubMed ID: 36583557
[TBL] [Abstract][Full Text] [Related]
6. Patient free text reporting of symptomatic adverse events in cancer clinical research using the National Cancer Institute's Patient-Reported Outcomes version of the Common Terminology Criteria for Adverse Events (PRO-CTCAE).
Chung AE; Shoenbill K; Mitchell SA; Dueck AC; Schrag D; Bruner DW; Minasian LM; St Germain D; O'Mara AM; Baumgartner P; Rogak LJ; Abernethy AP; Griffin AC; Basch EM
J Am Med Inform Assoc; 2019 Apr; 26(4):276-285. PubMed ID: 30840079
[TBL] [Abstract][Full Text] [Related]
7. Prostacyclin for pulmonary arterial hypertension.
Barnes H; Yeoh HL; Fothergill T; Burns A; Humbert M; Williams T
Cochrane Database Syst Rev; 2019 May; 5(5):CD012785. PubMed ID: 31042010
[TBL] [Abstract][Full Text] [Related]
8. Temporarily switching from oral to intravenous selexipag in patients with pulmonary arterial hypertension: safety, tolerability, and pharmacokinetic results from an open-label, phase III study.
Klose H; Chin KM; Ewert R; Gall H; Parambil J; Poch D; Seyfarth HJ; Axelsen LN; Hsu Schmitz SF; Stein C; Preston IR
Respir Res; 2021 Feb; 22(1):34. PubMed ID: 33536021
[TBL] [Abstract][Full Text] [Related]
9. Safety and tolerability of transition from inhaled treprostinil to oral selexipag in pulmonary arterial hypertension: Results from the TRANSIT-1 study.
Frost A; Janmohamed M; Fritz JS; McConnell JW; Poch D; Fortin TA; Miller CE; Chin KM; Fisher M; Eggert M; McEvoy C; Benza RL; Farber HW; Kim NH; Pfister T; Shiraga Y; McLaughlin V
J Heart Lung Transplant; 2019 Jan; 38(1):43-50. PubMed ID: 30391194
[TBL] [Abstract][Full Text] [Related]
10. Cognitive Interview-Based Validation of the Patient-Reported Outcomes Version of the Common Terminology Criteria for Adverse Events in Adolescents with Cancer.
Reeve BB; McFatrich M; Pinheiro LC; Freyer DR; Basch EM; Baker JN; Withycombe JS; Sung L; Mack JW; Waldron MK; Mowbray C; Palma D; Hinds PS
J Pain Symptom Manage; 2017 Apr; 53(4):759-766. PubMed ID: 28062347
[TBL] [Abstract][Full Text] [Related]
11. Cultural adaptation of the Italian version of the Patient-Reported Outcomes Common Terminology Criteria for Adverse Event (PRO-CTCAE®).
Caminiti C; Bryce J; Riva S; Ng D; Diodati F; Iezzi E; Sparavigna L; Novello S; Porta C; Del Mastro L; Procopio G; Cinieri S; Falzetta A; Calabrò F; Lorusso V; Cogoni AA; Tortora G; Maruzzo M; Passalacqua R; Cognetti F; Adamo V; Capelletto E; Ferrari A; Bagnalasta M; Bassi M; Nicelli A; De Persis D; D'Acunti A; Iannelli Patient E; Perrone F; Mitchell SA
Tumori; 2023 Jun; 109(3):324-334. PubMed ID: 35674125
[TBL] [Abstract][Full Text] [Related]
12. Development of the National Cancer Institute's patient-reported outcomes version of the common terminology criteria for adverse events (PRO-CTCAE).
Basch E; Reeve BB; Mitchell SA; Clauser SB; Minasian LM; Dueck AC; Mendoza TR; Hay J; Atkinson TM; Abernethy AP; Bruner DW; Cleeland CS; Sloan JA; Chilukuri R; Baumgartner P; Denicoff A; St Germain D; O'Mara AM; Chen A; Kelaghan J; Bennett AV; Sit L; Rogak L; Barz A; Paul DB; Schrag D
J Natl Cancer Inst; 2014 Sep; 106(9):. PubMed ID: 25265940
[TBL] [Abstract][Full Text] [Related]
13. A Special Focus on Selexipag - Treatment of Pulmonary Arterial Hypertension.
Sorensen LM; Wehland M; Kruger M; Simonsen U; Nassef MZ; Infanger M; Grimm D
Curr Pharm Des; 2017; 23(34):5191-5199. PubMed ID: 28891448
[TBL] [Abstract][Full Text] [Related]
14. Linguistic validation of the simplified Chinese version of the US National Cancer Institute's patient-reported outcomes version of the common terminology criteria for adverse events (PRO-CTCAE™).
Kkf C; Mitchell SA; Chan N; Ang E; Tam W; Kanesvaran R
BMC Cancer; 2020 Nov; 20(1):1153. PubMed ID: 33243173
[TBL] [Abstract][Full Text] [Related]
15. Patient-Reported Outcomes in Cancer Clinical Trials: Measuring Symptomatic Adverse Events With the National Cancer Institute's Patient-Reported Outcomes Version of the Common Terminology Criteria for Adverse Events (PRO-CTCAE).
Kluetz PG; Chingos DT; Basch EM; Mitchell SA
Am Soc Clin Oncol Educ Book; 2016; 35():67-73. PubMed ID: 27249687
[TBL] [Abstract][Full Text] [Related]
16. Validity and Reliability of the US National Cancer Institute's Patient-Reported Outcomes Version of the Common Terminology Criteria for Adverse Events (PRO-CTCAE).
Dueck AC; Mendoza TR; Mitchell SA; Reeve BB; Castro KM; Rogak LJ; Atkinson TM; Bennett AV; Denicoff AM; O'Mara AM; Li Y; Clauser SB; Bryant DM; Bearden JD; Gillis TA; Harness JK; Siegel RD; Paul DB; Cleeland CS; Schrag D; Sloan JA; Abernethy AP; Bruner DW; Minasian LM; Basch E;
JAMA Oncol; 2015 Nov; 1(8):1051-9. PubMed ID: 26270597
[TBL] [Abstract][Full Text] [Related]
17. Danish Translation and Linguistic Validation of the U.S. National Cancer Institute's Patient-Reported Outcomes version of the Common Terminology Criteria for Adverse Events (PRO-CTCAE).
Bæksted C; Nissen A; Pappot H; Bidstrup PE; Mitchell SA; Basch E; Dalton SO; Johansen C
J Pain Symptom Manage; 2016 Aug; 52(2):292-7. PubMed ID: 27090851
[TBL] [Abstract][Full Text] [Related]
18. Feasibility of Patient Reporting of Symptomatic Adverse Events via the Patient-Reported Outcomes Version of the Common Terminology Criteria for Adverse Events (PRO-CTCAE) in a Chemoradiotherapy Cooperative Group Multicenter Clinical Trial.
Basch E; Pugh SL; Dueck AC; Mitchell SA; Berk L; Fogh S; Rogak LJ; Gatewood M; Reeve BB; Mendoza TR; O'Mara AM; Denicoff AM; Minasian LM; Bennett AV; Setser A; Schrag D; Roof K; Moore JK; Gergel T; Stephans K; Rimner A; DeNittis A; Bruner DW
Int J Radiat Oncol Biol Phys; 2017 Jun; 98(2):409-418. PubMed ID: 28463161
[TBL] [Abstract][Full Text] [Related]
19. Linguistic Validation of the US National Cancer Institute's Patient-Reported Outcomes Version of the Common Terminology Criteria for Adverse Events in Korean.
Cho J; Yoon J; Kim Y; Oh D; Kim SJ; Ahn J; Suh GY; Nam SJ; Mitchell SA
J Glob Oncol; 2019 Mar; 5():1-10. PubMed ID: 30917069
[TBL] [Abstract][Full Text] [Related]
20. Linguistic validation of the Spanish version of the National Cancer Institute's Patient-Reported Outcomes version of the Common Terminology Criteria for Adverse Events (PRO-CTCAE).
Arnold B; Mitchell SA; Lent L; Mendoza TR; Rogak LJ; Barragán NM; Willis G; Medina M; Lechner S; Penedo FJ; Harness JK; Basch EM;
Support Care Cancer; 2016 Jul; 24(7):2843-51. PubMed ID: 26838022
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
